Fusion Pharmaceuticals Launches with a 25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments

Friday, February 24, 2017

Fusion Pharmaceuticals a newly formed biopharmaceutical company developing targeted alphaparticle radiotherapeutics for treating cancer today announced the closing of a 25 million Series A financing led by founding venture investor Johnson Johnson Innovation JJDC Inc with investments by HealthCap ..

Acticor Biotech Has Selected Its Contract Research Organisation to Manage Clinical Study Phase I

Friday, February 24, 2017

Acticor Biotech a biotechnology company focused on the treatment of acute ischemic stroke today announced that it selected its CRO Contract Research Organization to manage its clinical study phase I The firstinhuman study with ACT017 will be conducted at QPS facilities in Groningen the Netherland..

PMV Pharma Secures 74 Million in Series B Financing for Cancer Drugs Targeting p53

Thursday, February 23, 2017

PMV Pharmaceuticals Inc a leader in the discovery and development of p53targeted small molecule drugs for the treatment of cancer today announced the completion of a 74 million Series B financing round This financing was led by Topspin Biotech Fund and a group of investors with Euclidean Capital wit..

Lannett Provides Further Update On Methylphenidate ER Tablets

Thursday, February 23, 2017

Lannett Company Inc announced that it was notified by US Food and Drug Administration FDA late yesterday afternoon that FDA suspended indefinitely the deadline for the Company to submit materials in support of its request for a hearing to consider FDA39s proposal that Lannett withdraw its Abbreviate..

Envigos fully validated highly sensitive method enables completion of thyroid hormone tests in accordance with OECD guidelines Liquid chromatographymass spectrometry technique can detect T3 and T4 levels in 4 and 13 day old F1 rats

Wednesday, February 22, 2017

Envigo is pleased to announce that it has developed and validated a robust analytical method to evaluate the potential effects on thyroid hormone levels in rat F1 offspring It is now possible for Envigo to successfully determine levels of T3 triiodothyronine and T4 thyroxine hormones in serum from r..

Lysogene Receives Orphan Drug Designation from EMA for LYSGM101 for Treatment of GM1 Gangliosidosis

Wednesday, February 22, 2017

Lysogene a leading clinicalstage biotechnology company specializing in gene therapy for rare central nervous system diseases today announces that the European Medicines Agency EMA has granted orphan drug designation to LYSGM101 the Companys gene therapy drug candidate for treatment of GM1 Gangliosid..

Eagle Pharmaceuticals Announces New Patents Issued for Bendeka

Wednesday, February 22, 2017

Eagle Pharmaceuticals Inc announced that four additional patents have been issued related to Bendeka by the United States Patent and Trademark Office USPTO Patent numbers 9572796 and 9572797 will expire January 2031 Patent numbers 9572887 and 9572888 will expire March 2033 The US Patent and Trademar..

CohBar Inc Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

Wednesday, February 22, 2017

CohBar Inc a preclinical stage biotechnology company focused on developing mitochondria based therapeutics MBTs to treat agerelated diseases announced today that it has completed a study to evaluate the potential efficacy of its lead drug candidates MOTSc peptide analogs CB4209 and CB4211 in a welle..

Immuron Completes Phase II NASH Clinical Trial Recruitment

Tuesday, February 21, 2017

Immuron Limited an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products to target immunemediated diseases today announced that the Companys IMM124E Phase II clinical trial for the treatment of NASH NonAlcoholic Steatohepatitis has successfully rea..

Karolinska Development company Modus Therapeutics raises SEK 32 million to support development of sevuparin for sickle cell disease

Tuesday, February 21, 2017

Karolinska Development AB announces its portfolio company Modus Therapeutics AB a company focused on innovative treatments for patients with sickle cell disease has successfully completed a financing round raising SEK 32 million USD 36 million from existing investors KDev Investments stersjstiftelse..

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Monday, February 20, 2017

Exelixis Inctoday announced results from a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors The primary endpoint of the trial is to determine the dose limiting toxicity DLT and recommended phase 2 doses o..

LYNPARZA olaparib Meets Primary Endpoint in Phase III Trial in BRCAMutated Metastatic Breast Cancer

Monday, February 20, 2017

AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA olaparib tablets 300mg twice daily to physicians choice of a standard of care chemotherapy in the treatment of patients with HER2negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutat..

Russian Government drive to increase domestic manufacturing fuelling growth at CPhI Russia

Monday, February 20, 2017

CPhI Russia IPhEB cphirussia returns to the Russian capital taking place at the JSC VDNH VVC Moscow 28th30th March as the Governments Pharma 2020 plan continues to stimulate demand for international pharmaceutical ingredients manufacturing and packaging equipment The events 4th edition will see th..

The Most Awaited Conference of Chicago Drug Discovery and Development 2017

Saturday, February 18, 2017

Innovations and Advancements in Drug Discovery Changing the Topography of Pharmaceutical Industry Rapidly The demand for drug discovery technologies in the region of North America also gains from highincome population collectively promising healthy potential returns on investments due to high ado..

US FDA Expands Approval of Tiotropium Respimat for Maintenance Treatment of Asthma in Children

Friday, February 17, 2017

Boehringer Ingelheim today announced that the US Food and Drug Administration FDA approved tiotropium Respimat marketed as SPIRIVA Respimat for the longterm oncedaily maintenance treatment of people with asthma aged 6 years and older who continue to experience symptoms despite their other maintenanc..

Ascendis Pharma AS Announces Publication of Comprehensive Results from Randomized ActiveControlled Phase 2 Trial of OnceWeekly TransCon Growth Hormone in Pediatric Patients

Friday, February 17, 2017

Ascendis Pharma AS a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases today announced the publication of its previously presented pediatric phase 2 trial of TransCon Growth Hormone in the Journal of Clinical Endocr..

Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEAAPOaLRx and AKCEAAPOCIIILRx

Friday, February 17, 2017

Ionis Pharmaceuticals Incand Akcea Therapeutics a whollyowned subsidiary of Ionis Pharmaceuticals Inc announced today they have closed on their exclusive worldwide option and collaboration agreement with Novartis to develop and commercialize AKCEAAPOaLRx and AKCEAAPOCIIILRx following clearance under..

Clintec marks 20th year of global clinical research with launch of new brand

Thursday, February 16, 2017

Clintec today announces the launch of its new brand identity reflected in their newly created website This in part marks Clintecs 20th anniversary and the achievement of significant milestones following another year of substantial growth together with a succession of key appointments that have enha..

Pharmapack Europe 2017 highlights new developments in pharma packaging and drug delivery

Thursday, February 16, 2017

Pharmapack Europe organised by UBM EMEA closed its 2017 edition celebrating its 20 years as the leading European event for pharmaceutical packaging and drug delivery devices The top trends that emerged from the twoday event included patient centricity traceability innovation compliance and adheren..

Sanarias PfSPZCVac Vaccine Achieves High Level Protection Against Malaria in Clinical Trial

Thursday, February 16, 2017

In a report published today in Nature Sterile protection against human malaria by chemoattenuated PfSPZ vaccine investigators from the University of Tbingen reported all nine subjects 100 immunized with three doses of Sanaria PfSPZCVac malaria vaccine in a recently completed clinical trial were prot..

TOP